Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-12-21
Based on 561 first isolates · SURG · Skin / wound infection · 2024-12-22 → 2025-12-21
Surgery
Per-organism detail: SURG wound resistance view →
No single agent reaches 80 % coverage for this profile. Highest coverage without active warning:
vancomycin 55 % (51 %–59 %)
Best two-drug combination: vancomycin + meropenem covers 99 % (98 %–100 %)
Take cultures before treatment; consider a combination and discuss with infectious diseases if the patient is severely ill.
Not covered: Pseudomonas aeruginosa (14 %), Escherichia coli (11 %), Proteus mirabilis (9 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
vancomycin VAN
trend · Staphylococcus aureus Gram-positive only
55 %
57 %
n = 30
meropenem MEM
trend · Pseudomonas aeruginosa reserve
44 %
43 %
n = 30
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
43 %
33 %
n = 30
41 %
40 %
n = 30
piperacillin-tazobactam TZP
trend · Pseudomonas aeruginosa broad spectrum
40 %
43 %
n = 30
ceftriaxone CRO
trend · Escherichia coli
27 %
27 %
n = 30
25 %
17 %
n = 30
21 %
30 %
n = 30
12 %
13 %
n = 30
mecillinam MEC
not for this site
0 %
0 %
n = 30
trimethoprim TMP
not for this site
0 %
0 %
n = 30
nitrofurantoin NIT
not for this site
0 %
0 %
n = 30

Most likely organisms for this profile

Staphylococcus aureus
45 %
Pseudomonas aeruginosa
14 %
Escherichia coli
11 %
Enterococcus faecalis
10 %
Proteus mirabilis
9 %
Citrobacter freundii
6 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.